Carmel Pharma, Inc. to Market and Distribute PhaSeal®, the Only Clinically-Proven Closed System Transfer Device Available Today

At the beginning of 2006, Carmel Pharma, Inc. applies its passion and undivided resources to the distribution and education of their own product, PhaSeal®--the only "clinically-proven" closed system transfer device available today. PhaSeal's unique design "contains the drug" which helps prevent occupational exposure to hazardous drugs in health care settings--a call to action required by The National Institute for Occupational Safety.

Columbus, OH (PRWEB) January 18, 2006 -- Carmel Pharma began to market and distribute PhaSeal® from its own company, Carmel Pharma Inc, based in Columbus Ohio as of January 2006.

PhaSeal is the only "clinically proven" closed system transfer device on the market today. It's unique design is meant to prevent environmental contamination and help protect healthcare employees through the preparation, administration and waste handling of hazardous drugs.

The National Institute for Occupational Safety (NIOSH) states that "working with or near hazardous drugs in health care settings may cause skin rashes, infertility, miscarriage, birth defects, and possibly leukemia or other cancers," quotes David Schneider, President of Carmel Pharma Inc. "The PhaSeal System contains the hazardous drug which prevents enviromental contamination, therefore providing healthcare workers a safer working environment. As the manufacturer, our sole focus is to continue to educate and be a valuable resource on this important safety issue."

PhaSeal's double membrane provides dry connections between system components and it's expansion chamber ensures aerosols and vapors are contained and neither over pressure or under-pressure occurs duing drug preparation.

PhaSeal was launched in the US in December of 2000 and today, more than 400 leading cancer facilities, such as MD Anderson, University of San Francisco, Standford and Texas Childrens Hospital have contributed to PhaSeal's outstanding growth. Carmel Pharma has recently been placed on the Deloitte´s Fast 500 EMEA List.

If you have questions or want more information on ordering PhaSeal, please contact Carmel Pharma, Inc. at
866-487-9250 or 614-841-0504.

Contacts:
Christine Crooks, Marketing Director Carmel Pharma, Inc.
Direct: 866-487-9250 ext. 202

Agneta Ekblad, VP Oncology Solutions Carmel Pharma Inc. Direct: 858-220-3583

David Schneider, President Carmel Pharma Inc.
Direct: 866-487-9250 ext. 201

# # #

Press Contact: Christine Crooks
Company Name: CARMEL PHARMA, INC.
Email: email protected from spam bots
Phone: 614-841-0504
Website: www.phaseal.com

¶ 10:50 AM